RNA interference (RNAi) is rapidly becoming the method of choice for the elucidation of gene function and the identification of drug targets. As with other oligonucleotide-based strategies, RNAi is envisioned to ultimately be useful as a human therapeutic. Unlike previous nucleic acid therapeutics, small interfering RNAs have the potential to elicit immune responses via interactions with Toll-like receptor 3 and trigger interferon responses like long, double-stranded RNA and its analogs, such as poly(I:C)1. Recently, the safety of siRNAs has been questioned because they have been shown to trigger an interferon response in cultured cells2,3,4,5. We show here that it is possible to administer naked, synthetic siRNAs to mice and downregulate an endogenous or exogenous target without inducing an interferon response.
This is a preview of subscription content
Subscribe to Journal
Get full journal access for 1 year
only $8.25 per issue
All prices are NET prices.
VAT will be added later in the checkout.
Tax calculation will be finalised during checkout.
Get time limited or full article access on ReadCube.
All prices are NET prices.
Alexopoulou, L., Holt, A.C., Medzhitov, R. & Flavell, R.A. Recognition of double-stranded RNA and activation of NF-κB by Toll-like receptor 3. Nature 413, 732–738 (2001).
Sledz, C.A., Holko, M., de Veer, M.J., Silverman, R.H. & Williams, B.R.G. Activation of the interferon system by short-interfering RNAs. Nat. Cell Biol. 5, 771–772 (2003).
Bridge, A.J., Pebernard, S., Ducraux, A., Nicoulaz, A.L. & Iggo, R. Induction of an interferon response by RNAi vectors in mammalian cells. Nat. Genet. 34, 263–264 (2003).
Moss, E.G. & Taylor, J.M. Small-interfering RNAs in the radar of the interferon system. Nat. Cell Biol. 5, 834–839 (2003).
Kim, D.-H. et al. Interferon induction by siRNAs and ssRNAs synthesized by phage polymerase. Nat. Biotechnol. 22, 321–325 (2004).
Elbashir, S.M. et al. Duplexes of 21-nucleotide RNAs mediate RNA interference in cultured mammalian cells. Nature 411, 494–498 (2001).
Song, E. et al. RNA interference targeting Fas protects mice from fulminant hepatitis. Nat. Med. 9, 347–351 (2003).
Jackson, A.L. et al. Expression profiling reveals off-target gene regulation by RNAi. Nat. Biotechnol. 21, 635–637 (2003).
Medzhitov, R. Toll-like receptors and innate immunity. Nat. Rev. Immunol. 1, 135–145 (2001).
Zuany-Amorim, C., Hastewell, J. & Walker, C. Toll-like receptors as potential therapeutic targets for multiple diseases. Nat. Rev. Drug Discov. 1, 797–807 (2002).
Lund, J.M. et al. Recognition of single-stranded RNA viruses by Toll-like receptor 7. Proc. Natl. Acad. Sci. USA 101, 5598–5603 (2004).
Diebold, S.S. et al. Innate antiviral responses by means of TLR7-mediated recognition of single-stranded RNA. Science 303, 1529–1531 (2004).
Heil, F. et al. Species-specific recognition of single-stranded RNA via toll-like receptor 7 and 8. Science 303, 1526–1529 (2004).
Matsumoto, M., Kikkawa, S., Kohase, M., Miyake, K. & Seya, T. Establishment of a monoclonal antibody against human Toll-like receptor 3 that blocks double-stranded RNA-mediated signaling. Biochem. Biophys. Res. Commun. 293, 1364–1369 (2002).
Hemmi, H. et al. A Toll-like receptor recognizes bacterial DNA. Nature 408, 740–745 (2000).
Zhao, Q., Temsamani, J., Iadarola, P.L., Jiang, Z. & Agrawal, S. Effect of different chemically modified oligodeoxynucleotides on immune stimuation. Biochem. Pharmacol. 51, 173–182 (1996).
Liu, L., Zhou, X., Shi, J., Xie, X. & Yuan, Z. Toll-like receptor-9 induced by physical trauma mediates release of cytokines following exposure to CpG motif in mouse skin. Immunology 110, 341–347 (2003).
Chow, J.C., Young, D.W., Golenbock, D.T., Christ, W.J. & Gusovsky, F. Toll-like receptor-4 mediates lipopolysaccharide-induced signal transduction. J. Biol. Chem. 274, 10689–10692 (1999).
Lecocq, M. et al. Uptake by mouse liver and intracellular fate of plasmid DNA after a rapid tail vein injection of a small or a large volume. J. Gene Med. 5, 142–156 (2003).
Andrianaivo, F. et al. Hydrodynamics-based transfection of the liver: entrance into hepatocytes of DNA that causes expression takes place very early after injection. J. Gene Med. 6, 877–883 (2004).
Matsumoto, M. et al. Subcellular localization of Toll-like receptor 3 in human dendritic cells. J. Immunol. 171, 3154–3162 (2003).
Ahmed-Nejad, P. et al. Bacterial CpG-DNA and lipopolysaccharides activate Toll-like receptors at distinct cellular compartments. Eur. J. Immunol. 32, 1958–1968 (2002).
Layzer, J.M. et al. In vivo activity of nuclease-resistant siRNAs. RNA 10, 766–771 (2004).
Wu, J.C., Sundaresan, G., Iyer, M. & Gambhir, S.S. Noninvasive optical imaging of firefly luciferase reporter gene expression in skeletal muscles of living mice. Mol. Ther. 4, 297–306 (2001).
Zender, L. et al. Caspase 8 small interfering RNA prevent acute liver failure in mice. Proc. Natl. Acad. Sci. USA 100, 7797–7802 (2003).
Durbin, R.K., Mertz, S.E., Koromilas, A.E. & Durbin, J.E. PKR protection against intranasal vesicular stomatitis virus infection is mouse strain dependent. Viral Immunol. 15, 41–51 (2002).
Whitmore, M.M. et al. Syntergistic activation of innate immunity by double-stranded RNA and CpG DNA promotes enhanced antitumor activity. Cancer Res. 64, 5850–5859 (2004).
Kariko, K., Bhuyan, P., Capodici, J. & Weissman, D. Small interfering RNAs mediate sequence-independent gene suppression and induce immune activation by signaling through Toll-Like Receptor 3. J. Immunol. 172, 6545–6549 (2004).
Sioud, M. & Sorensen, D.R. Cationic liposome-mediated delivery of siRNAs in adult mice. Biochem. Biophys. Res. Commun. 312, 1220–1225 (2003).
Hodges, B.L. et al. Long-term transgene expression from plasmid DNA gene therapy vectors is negatively affected by CpG dinucleotides. Mol. Ther. 10, 269–278 (2004).
The authors would like to thank Jean Lee and Hu Wong for critical blood chemistry and liver panel analyses. We thank Anton McCaffrey and Mark Kay for a donation of the plasmid used in our studies. J.D.H. acknowledges the Whitaker Foundation for a doctoral fellowship. S.H. is supported by an endowment in Molecular Pathology from the Las Madrinas Foundation at CHLA.
M.E.D. is a consultant to and has a financial interest in Insert Therapeutics, Inc.
RNase digestion of poly(I:C) and siRNA. (PDF 151 kb)
Synthetic siRNA does not alter mouse CBC or liver enzyme levels. (PDF 85 kb)
Degradation kinetics of synthetic siRNA in mouse serum. (PDF 193 kb)
Sequence-specific target down-regulation by siRNA in RAW-264.7 cells. (PDF 97 kb)
Synthetic siRNA accomplishes sequence-specific RNAi of an exogenous target in mice. (PDF 74 kb)
Lack of IL-12 and IFN-a induction by siRNA in C57BL/6 mice. (PDF 94 kb)
About this article
Cite this article
Heidel, J., Hu, S., Liu, X. et al. Lack of interferon response in animals to naked siRNAs. Nat Biotechnol 22, 1579–1582 (2004). https://doi.org/10.1038/nbt1038
Nature Reviews Drug Discovery (2021)
Molecular Therapy (2014)
EZH2-specific microRNA-98 inhibits human ovarian cancer stem cell proliferation via regulating the pRb-E2F pathway
Tumor Biology (2014)
Innate immunity activation involved in unprotected porcine auto-transplant kidneys preserved by naked caspase-3 siRNA
Journal of Translational Medicine (2013)
Scientific Reports (2013)